Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
RSII~"Initiatives for National Distribution of Scar Peptide Serum" https://www.otcmarkets.com/stock/RSII/news/Rising-Biosciences-Inc-To-Offer-Cannophen-to-Patients-in-Ohio-Florida-Launches-Initiatives-for-National-Distribution-of-?id=183879
"Rising Biosciences, Inc. To Offer Cannophen™ to Patients in Ohio, Florida; Launches Initiatives for National Distribution of Scar Peptide Serum"
OGRMF UPDATE: NEW International Division https://www.organigram.ca/latest/organigram-appoints-guillermo-delmonte-as-president-of-new-international-division-sets-ambitious-plan-for-international-expansion/
"Organigram appoints Guillermo Delmonte as President of new international division, sets ambitious plan for international expansion"
OGRMF Due Diligence: https://www.organigram.ca/assets/Investor-Deck/Organigram-Investors-Deck-Feb21-.pdf SKROL DOWN
$$OGRMF
New investors in Silicon Valley biotech (trading at .017/share) Arrayit Corporation (ARYC):
@Arrayit on Twitter
Please do your due diligence on this Silicon Valley biotech company and you will see what an extremely undervalued company this is. It is finally getting the attention it deserves
http://www.arrayit.com/
Arrayit Corporation (ARYC) leads and empowers the genetic, research, pharmaceutical, and diagnostic communities through the discovery, development and manufacture of proprietary life science technologies and consumables for disease prevention, treatment and cure.
http://stockcharts.com/h-sc/ui?s=Aryc
A list of Arrayit Corporation patents:
https://t.co/EMXlE743rz
Here's a few recent updates from their website. For more links @ Arrayit and $ARYC on Twitter.
Please follow ARYC on Facebook for more updates :)
Arrayit microarray technology platform customers featured widely in Wells Fargo report by top analyst Tim Evans arrayit.com/confidential/l…
Arrayit advances OEM relationship with global medical technology and supply leaders GE Healthcare Chicago IL www3.gehealthcare.com/en
Arrayit featured with market leaders Illumina, Fluidigm and Affymetrix by world business insights leader Owler owler.com
Arrayit reports numerous emails to advance audit completion with top public company accounting firm RRBB Somerset NJ rrbb.com
Arrayit reports $46,000 microarray services sale to a leading proteomics research company located in the central USA
(link: http://arrayit.com/Services/services.html)
arrayit.com/Services/servi…
Arrayit reports $190,000 microarray services sale to a top research laboratory located in the Southern United States
(link: http://arrayit.com/Services/services.html)
arrayit.com/Services/servi…
?@arrayit?
Arrayit reports Parkinson's Disease Test PDx™ partnering opportunity with top physician in Molecular Medicine India
(link: http://nimhans.ac.in)
nimhans.ac.in
Arrayit reports $35,000 microarray services sale to a leading research laboratory specializing in complex pathways
(link: http://arrayit.com/Services/services.html)
arrayit.com/Services/servi…
Arrayit reports $168,000 microarray platform sale to leading medical suppliers Medi Laser located in Lahore Pakistan (link: http://www.medilaser.com.pk) medilaser.com.pk
Arrayit reports $100,000+ microarray services sale to a leading US-based research laboratory (link: http://arrayit.com/Services/services.html) arrayit.com/Services/servi…
Arrayit provides additional samples for $2.9 million microarray tech sale to United States Department of Defense DOD
http://www.
defense.gov
Arrayit microarray platform used by customers at University Medicine Bethesda MD to publish cancer research advance
www.twitter.com/arrayit
Arrayit schedules business development meeting today with top Vietnamese biotech firm regarding $10MM+ potential microarray growth account.
Arrayit customers in Toronto Canada use Arrayit microarray technology to publish advance on heart transplantation
http://
journals.plos.org/plosone/articl
e?id=10.1371/journal.pone.0151224
…
Arrayit signs 3-year $24.4 million patented microarray technology sales and marketing agreement with a leading laboratory services provider.
Arrayit reports record blood card sales in Q3-16 on microarray immunoassay research apps http://www.arrayit.com/Produc
Arrayit customers in Tel Aviv Israel use Arrayit microarray technology to publish bioprosthetic heart valve advance
http://
onlinelibrary.wiley.com/doi/10.1111/xe
n.12260/full
…
Arrayit quotes $160,000 microarray platform to molecular diagnostic leader Akonni Biosystems http://www.akonni.com
Arrayit reports $18,500 microarray platform sale life sciences leader ChemBio Moscow Russia
?http://www.?
?chembio.ru?
Arrayit reports $34,500 SpotBot 4 Microarray platform sale, leading European Distributor Grupo Taper Sintra Portugal http://www.arrayit.com/Products/Microarrayers/Microarrayer/microarrayer.html …
Arrayit reports microarray sale to testing leader RDL Reference Laboratory Los Angeles CA http://www.rdlinc.com
Arrayit ships $40,000 microarray platform life sciences leader Daemyung Sciences Seoul Korea http://www.dm4you.com
Arrayit signs 3-year $24.4 million patented microarray technology sales and marketing agreement with a leading laboratory services provider.
Arrayit customers from Arizona State use Arrayit microarray technology to publish adult stem cell therapy advance
http://www.
sciencedirect.com/science/articl
e/pii/S1873506115000598
…
Can an antibody microarray made with Arrayit technology replace in-situ hybs in HER2 breast cancer diagnostics?...
?http://?
?fb.me/2Xx9b1Oom?
Arrayit reports $30,000 microarray services sale to a top research
Arrayit quotes $179,430 microarrays to biomedical leader Progenie Molecular Valencia España http://www.progenie-molecular.com
Arrayit quotes $51,680 microarrays to top leader De La Salle University Manila Philippines http://www.dlsu.edu.ph
Arrayit quotes $102,240 microarray platform to venture think tank Leading Technology Group http://www.leadingtechnology.co
Arrayit Corporation ?@arrayit
Arrayit completes conference call on huge DNA testing opportunity in massive market in India http://arrayit.com/Services/SNP_Genotyping/snp_genotyping.html …
Arrayit reports DNA testing inquiry from top agency in India. Market penetration of 0.1% would produce $48M revenues http://arrayit.com/Services/SNP_Genotyping/snp_genotyping.html …
Arrayit Corporation ?@arrayit
Arrayit quotes $235,000 microarray instruments to top lab University Ottawa Ontario Canada http://www.uottawa.ca
Arrayit reports microarray sale to advanced technology leaders Waki Company Tokyo Japan http://waki-bg.jp
Arrayit reports microarray sale to automated molecular testing leader AutoGenomics Vista CA http://www.autogenomics.com
Arrayit reports microarray sale to life sciences European Biotech Network Dolembreux Belgium http://www.euro-bio-net.com
Arrayit reports microarray sale to top medical researcher at $13.4B endowed MIT Cambridge MA http://web.mit.edu
Arrayit expands marketing on $100K TissueMax™ Automated and Personal Tissue Microarrayers sale
$PMCB PharmaCyte Discusses Phase 2b Clinical Trial in Pancreatic Cancer PMCB
LAGUNA HILLS, Calif.--(BUSINESS WIRE)-- PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today explains PharmaCyte’s plans to conduct a Phase 2b clinical trial.
When PharmaCyte met with the FDA in January of 2017, PharmaCyte’s pre-IND meeting submission was predicated on PharmaCyte conducting a Phase 2b trial. During discussions with the U.S. Food and Drug Administration (FDA), PharmaCyte asked whether the data from that planned trial could be considered “pivotal” and thus support registration for marketing purposes. The FDA indicated that this was a possibility, but that the trial would have to be much larger than PharmaCyte was planning and the data would have to be markedly superior to the data seen with the comparator treatment.
PharmaCyte’s decision to conduct a Phase 2b trial rather than a pivotal trial was made relatively recently based on advice from PharmaCyte’s consulting oncologists, Chief Medical Officer and information obtained from PharmaCyte’s Advisory Board. PharmaCyte must rely on data from two European trials from 27 patients that were conducted about 20 years ago. The data from these trials are incomplete when compared to what is now required by the FDA to support a pivotal trial.
The Phase 2b trial is designed to determine how effective and safe multiple courses of ifosfamide will be in patients with locally advanced, non-metastatic, inoperable pancreatic cancer (LAPC) and how PharmaCyte’s treatment compares to a commonly used treatment for LAPC after patients’ tumors no longer respond following 4 to 6 months of the combination therapy of gemcitabine and Abraxane®. PharmaCyte is designing a Phase 2b clinical trial that, if successful, it believes will give the company a much more solid foundation for dealing with the FDA with the goal of bringing its pancreatic cancer therapy to market.
The planned Phase 2b trial will be significantly larger than the original Phase 2b trial PharmaCyte previously discussed with the FDA and will include multiple courses of low dose ifosfamide (the earlier trials used only two courses). This trial will also provide better statistical analyses of PharmaCyte’s therapy for LAPC and the comparator arm in terms of survival and safety. Also, the possibility exists that if the data from PharmaCyte’s therapy are significantly better than the data from the comparator arm, this may allow PharmaCyte to apply to the FDA for accelerated approval.
About PharmaCyte Biotech
PharmaCyte Biotech is a clinical stage biotechnology company developing cellular therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®.” This technology will be used as a platform upon which therapies for several types of cancer and diabetes are being developed.
PharmaCyte’s therapy for cancer involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active or “cancer-killing” form. For pancreatic cancer, these encapsulated cells are implanted in the blood supply to the patient’s tumor as close as possible to the site of the tumor. Once implanted, a chemotherapy drug that is normally activated in the liver (ifosfamide) is given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been implanted. When the ifosfamide flows through pores in the capsules, the live cells inside act as a “bio-artificial liver” and activate the chemotherapy drug at the site of the cancer. This “targeted chemotherapy” has proven effective and safe to use in past clinical trials and results in no treatment related side effects. PharmaCyte’s therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes involves encapsulating a human cell line that has been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the human body. The encapsulation will be done using the Cell-in-a-Box® technology. Once the encapsulated cells are implanted in a diabetic patient, they will function as a “bio-artificial pancreas” for purposes of insulin production.
Safe Harbor
This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans," "will," "outlook" and similar expressions. Forward-looking statements are based on management's current plans, estimates, assumptions and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement because of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements due to the impact of numerous risk factors, many of which are discussed in more detail in our Annual Report on Form 10-K and our other reports filed with the Securities and Exchange Commission.
More information about PharmaCyte Biotech can be found at www.PharmaCyte.com. Information may also be obtained by contacting PharmaCyte’s Investor Relations Department.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180228005518/en/
Investor Relations:
PharmaCyte Biotech, Inc.
Dr. Gerald W. Crabtree
Investor Relations Department
917.595.2856
Info@PharmaCyte.com
Source: PharmaCyte Biotech, Inc.
Released February 28, 2018
$RAD Starbucks Chief to Help Fuse Albertsons, Rite Aid RAD
https://www.wsj.com/articles/former-starbucks-chief-to-help-fuse-albertsons-rite-aid-1520226061Former
$DFFN PHASE 3 GBM TRIAL UNDERWAY; PLANNING FOR PHASE 2 TRIAL IN STROKE DFFN
http://scr.zacks.com/News/Press-Releases/Press-Release-Details/2018/DFFN-Phase-3-GBM-Trial-Underway-Planning-for-Phase-2-Trial-in-Stroke-article/default.aspx
$EQLB EQ LABS, INC. FLAGSHIP PRODUCT LAST SHOT EXPANDING INTO THE NORTHERN NEVADA MARKET EQLB
EQ LABS, INC. FLAGSHIP PRODUCT LAST SHOT EXPANDING INTO THE NORTHERN NEVADA MARKET
Print
Alert
EQ LABS, INC. FLAGSHIP PRODUCT LAST SHOT EXPANDING INTO THE NORTHERN NEVADA MARKET
Today, EQ Labs, Inc. (Pink Sheets: EQLB) reveled their plans to expand into the Reno/Lake Tahoe market. Starting January 1, 2018, the Last Shot premium recovery drink will be available in select ski resorts, golf courses, casinos, bars and convenience stores. Maurice Owens, President/CEO, announced the Directors of Sales and Marketing for the Northern Nevada expansion. Long-time residents and businessmen/women of the Reno/Lake Tahoe market Tim Dick, Isabel Billman, Kevin Hearn and Ana Basa will be spearheading EQ Labs latest move to dominate the recovery drink market in Nevada.
Contact Information:
EQ ENERGY DRINK, Inc.
Maurice Owens, President and CEO
Phone: (702) 806-5943
Web: www.Drinkeqlastshotlv.com
Email: mo@drinklastshotlv.com
Twitter: eqceo
https://ih.advfn.com/p.php?pid=nmona&article=76295080
$BMSN Regen BioPharma, Inc. Begins In Vivo Assessment of Small Molecule Agonists to NR2F6 Nuclear Receptor BMSN
Early data suggest molecules are stable and may be delivered orally
SAN DIEGO, California, November 27, 2017 /PRNewswire/ --
Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP) has initiated in vivo and ex vivo assessments to determine the effects of some of the Company's NR2F6 small molecule agonists in live rats and in tissues derived from humans and rats. Key attributes that are being measured include pH, plasma and liver microsomal stability, along with pharmacokinetics.
The NR2F6 nuclear receptor has been identified as a potentially very important immune cell inhibitor (an immune checkpoint) and cancer stem cell differentiator. The NR2F6 program at Regen aims to identify agonists which should suppress the immune system in diseases where the immune system is over-activated, such as autoimmunity. The program also aims to identify antagonists of NR2F6 in an effort to unleash the cancer-killing potential of a patient's own immune system..
"Initial studies are quite positive. Our compounds are stable at pH 2 and 7, stable in rat and human plasma, additionally one of our compounds shows very nice pharmacokinetics with an oral or intravenous half-life of about 2.5 hrs," says Harry Lander, Ph.D., MBA, President and Chief Scientific Officer of Regen. "Getting this data early in the process informs us of any liabilities the compounds may have which we would need to address via medicinal chemistry. So far, these molecules look like they will be orally deliverable and will not require too much more tweaking before we can start testing them for efficacy."
"I am very pleased that we have entered the phase of development where we are now testing these drugs in vivo and ex vivo," says David Koos, Ph.D., Chairman & CEO Regen BioPharma Inc. "These experiments we are currently involved with now will determine the path we proceed with going forward."
About Regen BioPharma Inc.:
Regen BioPharma Inc. is a publicly traded biotechnology company (OTCQB: RGBP) and (OTCQB: RGBPP). The Company is focused on the immunology and immunotherapy space. The Company is focused on rapidly advancing novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is focused on small molecule therapies for treating cancer and autoimmune disorders. Additional information on Regen BioPharma is available at http://www.regenbiopharmainc.com.
Disclaimer: This news announcement may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
CONTACT INFORMATION
Regen BioPharma Inc.
David R. Koos, Ph.D.
Chairman & Chief Executive Officer
+1-619-702-1404 Phone
+1-619-330-2328 Fax
http://www.regenbiopharma.com
david.koos@regenbiopharma.com
SOURCE Regen BioPharma, Inc.
$BLUU Security Details
Share Structure
Market Value1 $209,471 a/o Nov 21, 2017
Authorized Shares 4,995,000,000 a/o Nov 01, 2017
Outstanding Shares 2,094,706,872 a/o Nov 01, 2017
-Restricted Not Available
-Unrestricted Not Available
Held at DTC Not Available
Float 114,914,802 a/o Aug 17, 2015
Par Value 0.001
$MTVX Ride For Your Life – The Motoped Black Ops Survival Bike
When the zombie apocalypse rolls around (which it will), you’re going to want to be prepared. This means supplies and transport. Motoped has you covered. The Motoped Survival Bike is the road train of bikes. It’s a super-hauler outfitted with a universal rack that accepts a multitude of bolt-on mounts, harnesses, and fittings, basically anything you can imagine. With a primary fuel tank complemented by the two optional side-mounted tanks, you can travel over 600km without the need to fill up.
This bike was built for the creative survivalist. It features a military inspired design featuring a 4130 Chromoly Single Tube Frame, Adjustable Front and Rear Suspension, Patented Jackshaft Pedal Drive System, Hayes 9? Hydraulic Front and Rear Disc Brakes and Durable 24? and 26? wheels with a wider, thicker, dual wall design. There are several different engine sizes available that are maxed out at 125cc. The 125cc version features a kick-start, while the 49cc is electric. Just pack your gear on the back of the survival bike and escape from your life or with it, depends on the situation.
$AVEW AVEW HOLDINGS Announces Status of Central Texas Plant Sites for Precious Metal Recovery Processing Plant AVEW
https://www.otcmarkets.com/stock/AVEW/news/AVEW-HOLDINGS-Announces-Status-of-Central-Texas-Plant-Sites-for-Precious-Metal-Recovery-Processing-Plant?id=159533
$BSSP IMMUNE-THERAPEUTIC PROTEIN (ITP) BSSP
IMMUNE-THERAPEUTIC PROTEIN (ITP) is a therapeutic protein isolated from porsine pepsin which is irreversible, modified, and fractionate to the sequence Irreversible Pepsine Fraction (IPF).
The ITP contains Irreversible Pepsin Fraction with Mol.wt. 36kD. as an active ingridient modulate with Vitamin-C ester. This protein is precipitated specifically with blood serum proteins from area of alpha-1 and alpha-2 microglobulines. This reaction is different in the cases with and without cancer. In cases with advanced cancer growth, the serum reaction fades away. Using the IPF, it can obtain a new subset of T- cells, sensibilized against a patient’s cancer cells. The therapeutic effect process is similar to the “host rejection reaction” after unsuccessful organ transplantation. After the fourth week, a change in urine smell occurs which implies the presence of tumor tissue necrosis. IPF appears to modulate helper T1 cells’ expression of elaborate cytokines INFy, IL-2, which selectively promote cell-mediated immune response and subsequently stimulate cytotoxic lymphocytes. These lymphocytes have a prominent role in the host’s immunologic response to malignan cells. Proteins encoded by these pathogens enter the endogenous pathway for antigen presentation and are expressed on the surface of the infected cell as a complex with class I MHC – proteins. IPF appears to present a novel mechanism to reduce viral burden and stimulate innate immune responses to the virus for patients with significant malignan influence .
http://www.cantechholding.com/itp/
$AZFL Hemp full plant extract AZFL
https://azhempusa.com/en/details?lang=en&new=03
Amazonas Florestal Ltd. Announced Today That The Company's Subsidiary Amazon Hemp will be selling their new products on Bonsai MedSpa located in Miami. Coming soon in our website and in the best online sites!
Amazon Hemp Team
$APPZ An application that does it all.
https://www.caminoaero.com/Home/About
CaminoAero has been created by a group of aviation and software development professionals, to provide effective software applications for the aviation community. The idea was born during the purchase of an aircraft, where many hours were spent scouring through page after page of aircraft log books.The seller of the aircraft was unable to present a clear picture of if, and when, each Airworthiness Directive, Inspection and Service Bulletin was completed, or more importantly, not completed.
Working through this frustration and after some further investigation into how other aircraft owners tracked their maintenance activities, we discovered that most followed their aircraft's maintenance with either (1) the use of a white board; or (2) hours spent building complex spreadsheets (some did nothing at all, and left this important role to their entrusted AME – who had dozens of other aircraft to care for). These poor, inefficient practices were all because existing software was too costly. During the initial formulation of the idea we discovered that there were no cost-effective solutions available in the market for private aircraft owners. We combined this simple concept with the inclusion of Pilot Flight Log, which we felt was a natural and useful companion tool. We are the first company to bring these two features together, and we intend to be the best at it, all while staying affordable and reliable for private aircraft owners.
$ZMRK ~ Welcome to Zalemark Holding Co.; Inc. (ZMRK) DD
$MCGI OUR VISION MCGI
Want to see your friend’s vacation pictures or the latest Kardashian trends? Go to Facebook.Ready to advance your nursing career and start connecting with top nursing organizations and industry leaders? You found the right place.Our vision is to connect every nursing school, association, employer, and over 1,000,000 nurses in the Nurses Lounge. Imagine, the entire nursing industry under one roof. It’s possible we just need your help. Join today…it’s free for nurses, nursing schools, associations, and employers!
http://www.nurseslounge.com/home/about-us/
$LVGI real products all over AMAZON store LVGI
https://smile.amazon.com/s/ref=nb_sb_noss_2?url=search-alias%3Daps&field-keywords=HEMPCORE
Amazon Choice
https://smile.amazon.com/HempCore-Supplement-Optimize-Cognitive-Function/dp/B01KH4KC4W/ref=ice_ac_b_dpb?ie=UTF8&qid=1516670505&sr=8-4&keywords=HEMPCORE
$ITKH https://oracledispatch.com/2018/03/01/iteknik-holding-corp-otcmktsitkh-rising-solid-fundamentals/Iteknik Holding Corp (OTCMKTS:ITKH) is Rising on Solid Fundamentals
The Oracle Dispatch - Mar 1, 2018
Iteknik Holding Corp (OTCMKTS:ITKH) has been booming up the chart over the last month and even with some recent volatility, the stock is still up over 200%.Iteknik Holding Corp (OTCMKTS:ITKH) is Rising on Solid Fundamentals
The Oracle Dispatch - Mar 1, 2018
Iteknik Holding Corp (OTCMKTS:ITKH) has been booming up the chart over the last month and even with some recent volatility, the stock is still up over 200%.
$DFCO https://grovecityreview.com/dalrada-financial-dfco-charts-showing-bullish-signals/37710/Dalrada Financial (DFCO) Charts Showing Bullish Signals
GCR - 21h ago
The base for this indicator is the security's price. It takes four steps to get from the actual price to the MACD-Histogram. Chartists should keep this in mind when analyzing the MACD-Histogram.Dalrada Financial (DFCO) Charts Showing Bullish Signals
GCR - 21h ago
The base for this indicator is the security's price. It takes four steps to get from the actual price to the MACD-Histogram. Chartists should keep this in mind when analyzing the MACD-Histogram.
$ASKH https://insiderfinancial.com/the-transaction-of-astika-holdings-inc-otcmktsaskh-is-an-opportunityAstika Holdings Inc (OTCMKTS:ASKH) Looks Like An Opportunity
Insider Financial - Feb 22, 2018
Shareholders of Astika Holdings Inc. (OTCMKTS:ASKH) must be right now counting their stock gains. After the company announced a Non-Binding Letter of Intent to acquire a Chinese cash cow entity, some have doubled their money (even more) in a very short ...Astika Holdings Inc (OTCMKTS:ASKH) Looks Like An Opportunity
Insider Financial - Feb 22, 2018
Shareholders of Astika Holdings Inc. (OTCMKTS:ASKH) must be right now counting their stock gains. After the company announced a Non-Binding Letter of Intent to acquire a Chinese cash cow entity, some have doubled their money (even more) in a very short ...
$ALES https://heraldks.com/big-rock-brewery-inc-br-is-yet-to-see-trading-action-on-mar-6/Big Rock Brewery Inc. (BR) Is Yet to See Trading Action on Mar 6
Herald KS - 11h ago
The S&P/TSX Composite Index is a free-float market-capitalization-weighted index like most leading indices in the world. This means that its components are the most actively traded stocks on the TSX, excluding those that are held by inside traders ...Big Rock Brewery Inc. (BR) Is Yet to See Trading Action on Mar 6
Herald KS - 11h ago
The S&P/TSX Composite Index is a free-float market-capitalization-weighted index like most leading indices in the world. This means that its components are the most actively traded stocks on the TSX, excluding those that are held by inside traders ...
$TVOG https://insiderfinancial.com/turner-venture-group-inc-otcmktstvog-to-keep-expanding-its-reach-in-the-energy-marketTurner Venture Group Inc (OTCMKTS:TVOG) To Keep Expanding its Reach in the Energy Market
Insider Financial - 1d ago
Turner Venture Group Inc (OTCMKTS:TVOG) has begun to prove that it just may be able to hold its own as a major player in the industry.Turner Venture Group Inc (OTCMKTS:TVOG) To Keep Expanding its Reach in the Energy Market
Insider Financial - 1d ago
Turner Venture Group Inc (OTCMKTS:TVOG) has begun to prove that it just may be able to hold its own as a major player in the industry.
$TPAC https://wolcottdaily.com/thai-plaspac-public-company-limited-tpac-rise-1-79-on-mar-7/Thai Plaspac Public Company Limited (TPAC) Rise 1.79% on Mar 7
Wolcott Daily - 1h ago
Shares of Thai Plaspac Public Company Limited (BKK:TPAC) last traded at 11.4, representing a move of 1.79%, or 0.2 per share, on volume of 25,000 shares.Thai Plaspac Public Company Limited (TPAC) Rise 1.79% on Mar 7
Wolcott Daily - 1h ago
Shares of Thai Plaspac Public Company Limited (BKK:TPAC) last traded at 11.4, representing a move of 1.79%, or 0.2 per share, on volume of 25,000 shares.
$MFST https://kaplanherald.com/2018/03/05/medifirst-solutions-mfst-needle-moving-20-00-on-volume/Medifirst Solutions (MFST) Needle Moving 20.00% on Volume
Kaplan Herald - 1d ago
Shares of Medifirst Solutions (MFST) have seen the needle move 20.00% or 0.0001 in the most recent session. The OTC listed company saw a recent bid of $0.0006 on 190010 volume.Medifirst Solutions (MFST) Needle Moving 20.00% on Volume
Kaplan Herald - 1d ago
Shares of Medifirst Solutions (MFST) have seen the needle move 20.00% or 0.0001 in the most recent session. The OTC listed company saw a recent bid of $0.0006 on 190010 volume.
$VRTHF https://utahherald.com/veritas-investment-management-uk-ltd-has-upped-its-taiwan-semiconductor-tsm-holding-veritas-pharma-ordinary-shares-cana-vrthf-si-decreased-by-60-15/Veritas Investment Management Uk LTD Has Upped Its Taiwan Semiconductor (TSM) Holding; VERITAS PHARMA ...
UtahHerald.com - 1d ago
VERITAS PHARMA INC ORDINARY SHARES CANA (OTCMKTS:VRTHF) had a decrease of 60.15% in short interest. VRTHF's SI was 31,400 shares in March as released by FINRA.Veritas Investment Management Uk LTD Has Upped Its Taiwan Semiconductor (TSM) Holding; VERITAS PHARMA ...
UtahHerald.com - 1d ago
VERITAS PHARMA INC ORDINARY SHARES CANA (OTCMKTS:VRTHF) had a decrease of 60.15% in short interest. VRTHF's SI was 31,400 shares in March as released by FINRA.
$FSSN https://reurope.com/2018/03/02/could-fision-corp-otcmktsfssn-skyrocket-the-stock-has-too-many-sellers/Could FISION CORP (OTCMKTS:FSSN) Skyrocket? The Stock Has Too Many Sellers
Reurope - Mar 2, 2018
The stock of FISION CORP (OTCMKTS:FSSN) registered an increase of 750% in short interest. FSSN's total short interest was 1,700 shares in March as published by FINRA.Could FISION CORP (OTCMKTS:FSSN) Skyrocket? The Stock Has Too Many Sellers
Reurope - Mar 2, 2018
The stock of FISION CORP (OTCMKTS:FSSN) registered an increase of 750% in short interest. FSSN's total short interest was 1,700 shares in March as published by FINRA.
$STMDF http://www.investorideas.com/news/2018/bitcoin/03063CSEJOB.aspStartMonday (CSE:JOB) (OTC:STMDF) (FRANKFURT:JOB) Boosts #Blockchain Development with New Talent
InvestorIdeas.com (press release) - 8h ago
AMSTERDAM, The Netherlands - March 6, 2018 (Investorideas.com Newswire) Smart recruitment technology firm StartMonday Technology Corp.StartMonday (CSE:JOB) (OTC:STMDF) (FRANKFURT:JOB) Boosts #Blockchain Development with New Talent
InvestorIdeas.com (press release) - 8h ago
AMSTERDAM, The Netherlands - March 6, 2018 (Investorideas.com Newswire) Smart recruitment technology firm StartMonday Technology Corp.
$NVCN http://www.stocksgallery.com/2018/03/06/neovasc-inc-nvcn-noted-a-price-change-of-3-05-and-paramount-group-inc-pgre-closes-with-a-move-of-0-42/Neovasc Inc. (NVCN) noted a price change of 3.05% and Paramount Group, Inc. (PGRE) closes with a move of -0.42%
Stocks Gallery - 13h ago
In latest trading activity; Neovasc Inc. (NVCN) snatched the consideration from Investors, when its current beneficial picture was seen that is promoting good health.Neovasc Inc. (NVCN) noted a price change of 3.05% and Paramount Group, Inc. (PGRE) closes with a move of -0.42%
Stocks Gallery - 13h ago
In latest trading activity; Neovasc Inc. (NVCN) snatched the consideration from Investors, when its current beneficial picture was seen that is promoting good health.
$AMLH https://globenewswire.com/news-release/2018/03/02/1414402/0/en/American-Leisure-Holdings-Inc-s-GG-Media-Network-excells-in-the-business-of-Esports-Media.htmlAmerican Leisure Holdings, Inc.'s GG Media Network excells in the business of Esports Media
GlobeNewswire (press release) - Mar 2, 2018
American Leisure Holdings, Inc. (OTC Pink:AMLH) has vastly expanded their access to technology and operational support areas through an agreement with Thunder Gaming.American Leisure Holdings, Inc.'s GG Media Network excells in the business of Esports Media
GlobeNewswire (press release) - Mar 2, 2018
American Leisure Holdings, Inc. (OTC Pink:AMLH) has vastly expanded their access to technology and operational support areas through an agreement with Thunder Gaming.
$ANDI https://oracledispatch.com/2018/03/03/andiamo-corp-otcmktsandi-looks-expand-shares-test-support/Andiamo Corp (OTCMKTS:ANDI) Looks to Expand as Shares Test Support
The Oracle Dispatch - Mar 3, 2018
Now commanding a market cap of $42.5M, ANDI has virtually no cash on the books, which stands against virtually no total current liabilities.Andiamo Corp (OTCMKTS:ANDI) Looks to Expand as Shares Test Support
The Oracle Dispatch - Mar 3, 2018
Now commanding a market cap of $42.5M, ANDI has virtually no cash on the books, which stands against virtually no total current liabilities.
$OGRMF https://chapmanherald.com/needle-tilting-mid-session-for-organigram-hldgs-inc-ogrmf-as-shares-move-2-69/56600/Needle Tilting Mid-Session For Organigram Hldgs Inc (OGRMF) As Shares Move 2.69%
Chapman Herald - 11h ago
Organigram Hldgs Inc (OGRMF) shares are moving today on volatility 2.69% or 0.089 from the open. The OTC listed company saw a recent bid of 3.4000 and 281900 shares have traded hands in the session.Needle Tilting Mid-Session For Organigram Hldgs Inc (OGRMF) As Shares Move 2.69%
Chapman Herald - 11h ago
Organigram Hldgs Inc (OGRMF) shares are moving today on volatility 2.69% or 0.089 from the open. The OTC listed company saw a recent bid of 3.4000 and 281900 shares have traded hands in the session.
Followers
|
157
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
20724
|
Created
|
04/07/17
|
Type
|
Free
|
Moderator $Pistol Pete$ | |||
Assistants mick |
PER MGMT DAVE -
IH Geek [Dave] DISCLAIMER |
01-31-2021
DISCLAIMER: ONLY FOR MICK
https://investorshub.advfn.com/boards/profilea.aspx?user=1012
*The Board Monitor and Board Assistants herewithin , are not licensed brokers and assume NO responsibility for actions,
investments,decisions, or messages posted on this forum.
CONTENT ON THIS FORUM SHOULD NOT BE CONSIDERED ADVISORY NOR SOLICITATION
AUTHORS MAY HAVE BUYS OR SELLS WITH THE COMPANIES MENTIONED IN TRADING POSTERS SHOULD DUE DILIGENT BUYING OR SELLING.
ALL POSTING SHOULD BE CONSIDERED FOR INFORMATION ONLY. WE DO NOT RECOMMEND ANYONE BUY OR SELL ANY SECURITIES POSTED HEREWITHIN.
ANY trade entered into risks the possibility of losing the funds invested.
• There are no guarantees when buying or selling any security.Any
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |